|
A Pilot Study of Topical Antiflammin-2 for Psoriasis Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about A Pilot Study of Topical Antiflammin-2 for Psoriasis conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Pilot Study of Topical Antiflammin-2 for Psoriasis Clinical research trials and A Pilot Study of Topical Antiflammin-2 for Psoriasis medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like A Pilot Study of Topical Antiflammin-2 for Psoriasis. A Pilot Study of Topical Antiflammin-2 for Psoriasis Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a A Pilot Study of Topical Antiflammin-2 for Psoriasis clinical trial. Test subjects typically obtain the finest healthcare available for their A Pilot Study of Topical Antiflammin-2 for Psoriasis condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Pilot Study of Topical Antiflammin-2 for Psoriasis  A Pilot Study of Topical Antiflammin-2 for Psoriasis
A Pilot Study of Topical Antiflammin-2 for Psoriasis
For Condition: Psoriasis
Status: Completed
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: This study is a pilot trial designed to evaluate topical antiflammin-2, a phospholipase A2 (PLA2) inhibitor, in the treatment of chronic plaque psoriasis. Antiflammin-2 in an ointment base, or the vehicle alone will each be applied four times per day to a single plaque in a randomized, double-blinded fashion.
Details: This study is a pilot trial designed to evaluate topical antiflammin-2, a phospholipase A2 (PLA2) inhibitor, in the treatment of chronic plaque psoriasis. Antiflammin-2 in an ointment base, or the vehicle alone will each be applied four times per day to a single plaque in a randomized, double-blinded fashion.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Patients must be age 18 or older. Patients male or female must use contraception if of childbearing age. No men and women actively attempting to conceive a child during the time of drug testing. No pregnant or nursing women. Patients must be otherwise healthy, immunocompetent, ambulatory patients with psoriasis who have more than 5 percent of their body surface area involved with the disease or who have localized disabling psoriasis. Have failed one prior topical treatment regimen including topical cortiscosteroids, coat tar preparations, or ultraviolet light. An ambulatory performance status of 0,1,2 (ECOG Scale). Ability to participate in an out -patient study and to provide informed consent. Creatinine less than 2.0 mg/100ml. Bilirubin less than or equal to 1.5 mg/100ml; prothrombin time less than or equal to 1.3 times control. WBC greater than 3000/mm(3), granulocytes greater than 1500/mm(3), platelets greater than 100,000/mm(3). No clinically significant cardiac disease. No patients with previously documented serious infectious diseases such as pneumocystis pneumonia, mycobacterium avium infection, etc. which would suggest clinically evident immunodeficiency. No systemic treatment for psoriasis (methotrexate, PUVA, UVB, cyclosporine, etc.) and topical treatments (corticosteroids, tar, anthralin, etc.) during the four weeks prior to study entry, and topical treatment during the two weeks prior to study entry.
Total Enrollment: 24
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 940048; 94-C-0048
Study Start Date: December 23, 1993
Record last reviewed: December 16, 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001371
Other Psoriasis Studies:
1. Study of Topical Calcitriol in Children With Psoriasis
2. Characterizing Serum Protein Patterns in Selected Skin Diseases
3. Research in Skin Inflammation
4. Study of Psoriatic Arthritis
5. A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
Related Studies:
Other Psoriasis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
A Pilot Study of Topical Antiflammin-2 for Psoriasis
|
|
|
|
|
|
|
|
